LINCOLN PHAR | DISHMAN CARBOGEN AMCIS | LINCOLN PHAR/ DISHMAN CARBOGEN AMCIS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 12.8 | -19.7 | - | View Chart |
P/BV | x | 2.1 | 0.6 | 343.4% | View Chart |
Dividend Yield | % | 0.3 | 0.0 | - |
LINCOLN PHAR DISHMAN CARBOGEN AMCIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
LINCOLN PHAR Mar-24 |
DISHMAN CARBOGEN AMCIS Mar-24 |
LINCOLN PHAR/ DISHMAN CARBOGEN AMCIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 754 | 283 | 266.6% | |
Low | Rs | 339 | 113 | 299.4% | |
Sales per share (Unadj.) | Rs | 289.8 | 166.8 | 173.7% | |
Earnings per share (Unadj.) | Rs | 46.6 | -9.8 | -475.9% | |
Cash flow per share (Unadj.) | Rs | 51.9 | 10.0 | 516.8% | |
Dividends per share (Unadj.) | Rs | 1.80 | 0 | - | |
Avg Dividend yield | % | 0.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 296.0 | 358.9 | 82.5% | |
Shares outstanding (eoy) | m | 20.03 | 156.78 | 12.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.9 | 1.2 | 158.8% | |
Avg P/E ratio | x | 11.7 | -20.2 | -58.0% | |
P/CF ratio (eoy) | x | 10.5 | 19.7 | 53.4% | |
Price / Book Value ratio | x | 1.8 | 0.6 | 334.6% | |
Dividend payout | % | 3.9 | 0 | - | |
Avg Mkt Cap | Rs m | 10,949 | 31,059 | 35.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1,029 | 12,082 | 8.5% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,806 | 26,158 | 22.2% | |
Other income | Rs m | 344 | 508 | 67.8% | |
Total revenues | Rs m | 6,150 | 26,666 | 23.1% | |
Gross profit | Rs m | 999 | 2,578 | 38.8% | |
Depreciation | Rs m | 106 | 3,109 | 3.4% | |
Interest | Rs m | 15 | 1,200 | 1.2% | |
Profit before tax | Rs m | 1,222 | -1,223 | -100.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 289 | 312 | 92.8% | |
Profit after tax | Rs m | 933 | -1,535 | -60.8% | |
Gross profit margin | % | 17.2 | 9.9 | 174.6% | |
Effective tax rate | % | 23.7 | -25.5 | -92.8% | |
Net profit margin | % | 16.1 | -5.9 | -274.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 4,719 | 19,282 | 24.5% | |
Current liabilities | Rs m | 1,174 | 25,547 | 4.6% | |
Net working cap to sales | % | 61.1 | -24.0 | -254.9% | |
Current ratio | x | 4.0 | 0.8 | 532.5% | |
Inventory Days | Days | 132 | 41 | 319.6% | |
Debtors Days | Days | 1,017 | 6 | 15,806.8% | |
Net fixed assets | Rs m | 2,536 | 76,424 | 3.3% | |
Share capital | Rs m | 200 | 314 | 63.9% | |
"Free" reserves | Rs m | 5,728 | 55,961 | 10.2% | |
Net worth | Rs m | 5,928 | 56,275 | 10.5% | |
Long term debt | Rs m | 0 | 2,456 | 0.0% | |
Total assets | Rs m | 7,254 | 95,706 | 7.6% | |
Interest coverage | x | 84.4 | 0 | -442,381.9% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.3 | 292.8% | |
Return on assets | % | 13.1 | -0.3 | -3,734.5% | |
Return on equity | % | 15.7 | -2.7 | -577.2% | |
Return on capital | % | 20.9 | 0 | -53,517.3% | |
Exports to sales | % | 62.4 | 0 | - | |
Imports to sales | % | 2.7 | 0 | - | |
Exports (fob) | Rs m | 3,625 | NA | - | |
Imports (cif) | Rs m | 156 | NA | - | |
Fx inflow | Rs m | 3,625 | 3,187 | 113.8% | |
Fx outflow | Rs m | 156 | 327 | 47.6% | |
Net fx | Rs m | 3,469 | 2,860 | 121.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 632 | 3,840 | 16.5% | |
From Investments | Rs m | -573 | -2,295 | 25.0% | |
From Financial Activity | Rs m | -52 | -222 | 23.4% | |
Net Cashflow | Rs m | 7 | 1,323 | 0.5% |
Indian Promoters | % | 49.8 | 59.3 | 83.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 5.2 | 9.4 | 55.3% | |
FIIs | % | 5.2 | 8.2 | 63.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 50.2 | 40.7 | 123.5% | |
Shareholders | 31,330 | 55,280 | 56.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare LINCOLN PHAR With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | LINCOLN PHAR | DISHMAN CARBOGEN AMCIS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.81% | -1.09% | 0.11% |
1-Month | -6.75% | 16.78% | -3.22% |
1-Year | -6.64% | 26.43% | 42.65% |
3-Year CAGR | 25.26% | -0.39% | 19.86% |
5-Year CAGR | 28.17% | 12.67% | 25.90% |
* Compound Annual Growth Rate
Here are more details on the LINCOLN PHAR share price and the DISHMAN CARBOGEN AMCIS share price.
Moving on to shareholding structures...
The promoters of LINCOLN PHAR hold a 49.8% stake in the company. In case of DISHMAN CARBOGEN AMCIS the stake stands at 59.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of LINCOLN PHAR and the shareholding pattern of DISHMAN CARBOGEN AMCIS.
Finally, a word on dividends...
In the most recent financial year, LINCOLN PHAR paid a dividend of Rs 1.8 per share. This amounted to a Dividend Payout ratio of 3.9%.
DISHMAN CARBOGEN AMCIS paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of LINCOLN PHAR, and the dividend history of DISHMAN CARBOGEN AMCIS.
For a sector overview, read our pharmaceuticals sector report.
On Thursday, Indian share markets traded lower throughout the trading session and ended on a weak note.